此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

评估 BAT1706 注射液不同制造批次的比较药代动力学研究

2026年9月28日 更新者:Bio-Thera Solutions

一项随机、双盲、单剂量、平行双臂研究,以比较不同生产批次(新工艺和旧工艺)的 BAT1706 注射液在健康受试者中的药代动力学和安全性

This is a randomized, double-blind, single-dose, parallel two-arm study to compare the pharmacokinetics, safety, and immunogenicity of BAT1706 Injection from different manufacturing batches (by new process and old process) in healthy male subjects.

研究概览

地位

完全的

条件

详细说明

A total of 38 subjects are planned to be enrolled and randomized in a 1: 1 ratio to receive a single intravenous drip of BAT1706 Injection (by old process) or BAT1706 Injection (by new process) at 1 mg/kg body weight.

A 7-day screening period will be set up for this study. Subjects will be admitted to the hospital 1 day pre-dose (Day -1) and discharged after completing relevant observations and assessments 24 h post-dose. After discharge, subjects should return to the hospital for 12 follow-up visits according to the requirements of this study, on Days 3, 4, 5, 8, 11, 15, 22, 29, 36, 43, 57 and 71 post-dose.

研究类型

介入性

注册 (实际的)

38

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Anhui
      • Hefei、Anhui、中国
        • The Second Affiliated Hospital of Anhui Medical University

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 45年 (成人)

接受健康志愿者

是的

有资格学习的性别

男性

描述

Inclusion Criteria:

  1. Healthy male subjects aged between 18 and 45 years with body mass index (BMI) between 18.0 and 28.0 kg/m2 and body weight between 50 and 100 kg (inclusive);
  2. Subjects for whom the results of physical examination, vital signs, 12-lead ECG, and laboratory tests are normal or abnormal without clinical significance;
  3. Subjects who do not smoke, or smoke no more than 5 cigarettes per day for < 10 years;
  4. Subjects who agree to use effective contraception (including but not limited to: hormonal contraception, physical contraception, or abstinence) from the time of signing the informed consent form until 6 months after intravenous drip of the study drug;
  5. Subjects who are willing and able to follow the visits, treatments, laboratory tests, and other relevant procedures specified in this study.

Exclusion Criteria:

  1. Subjects who have previous or current clinically significant gastrointestinal disorder (including diverticulitis, gastric ulcer), renal disorder, liver disorder, cardiovascular disorder, hematological disorder, lung disorder, nervous system disorder, metabolic disorder (including known diabetes mellitus), psychosis, or allergic disease (excluding mild asymptomatic seasonal allergy) at screening/enrollment, and in the opinion of the investigator, are not suitable for participation in this clinical study;
  2. Subjects who have psychiatric disorders, or in the opinion of the investigator, are not suitable for participation in this clinical study (e.g., he is considered unable to understand or follow the relevant requirements of the study, or some of his existing conditions may result in additional risks associated with participation in this study);
  3. Subjects who have previous or current clinically significant allergies (excluding mild asymptomatic seasonal allergy); or subjects who have known or suspected allergy or hypersensitivity to any component of the study drug; or subjects who have known or suspected hypersensitivity to Chinese hamster ovary cell products or other recombinant human or humanized antibodies;
  4. Subjects who have a tendency to haemorrhage or thrombosis, or have a history of non-traumatic haemorrhage with appropriate clinical treatment, or have a history of thrombosis, or have any disease that may increase the risk of haemorrhage or thrombosis (e.g., abnormal coagulation, thrombocytopenia, or INR > 1.5);
  5. Subjects who have any previous malignancy including lymphoma, leukemia, and skin cancer;
  6. Subjects who have abnormal and clinically significant ECG (as judged by the investigator), or corrected QT interval according to Bazett's formula > 470 ms (Bazett's formula: Q-Tc = QT/(R-R)0.5, where R-R represents the interval between two R waves in s);
  7. Subjects who have a history of hypertension, or systolic blood pressure > 145 mmHg or diastolic blood pressure > 95 mmHg at screening/enrollment;
  8. Subjects who have clinically significant chronic or acute infection at screening/enrollment; or have any positive result for HBV surface antigen, HCV antibody, HIV antibody, and treponema pallidum antibody at screening;
  9. Subjects who have previously used Bevacizumab or VEGF-targeting agents;
  10. Subjects who have used any biological product within 3 months prior to enrollment, or have used any monoclonal antibody within 9 months prior to enrollment;
  11. Subjects who have used prescription or over-the-counter drugs within 14 days prior to enrollment, or less than 5 half-lives have passed from the last dose to the dosing day of this study, whichever is longer;
  12. Subjects who have used any Chinese herbal medicine within 14 days prior to enrollment;
  13. Subjects who have participated in other drug clinical trials within 3 months prior to enrollment, or propose to participate in other drug clinical trials during this study;
  14. Subjects who have received live virus vaccine within 12 weeks prior to screening, or plan to receive live virus vaccine during the study;
  15. Subjects who have undergone major injury, surgery, or fracture within 4 weeks prior to enrollment, or propose to undergo surgery during the study;
  16. Subjects who have donated blood or have blood samples > 400 mL collected as subjects within 3 months prior to screening, or plan to donate blood during the study;
  17. Subjects who have a history of alcohol dependence, or have a positive alcohol test result at screening/baseline;
  18. Subjects who have consumed alcoholic beverages within 48 h prior to enrollment;
  19. Subjects who have a history of drug abuse, or have a positive drug abuse test result at screening/baseline;
  20. Subjects who cannot follow the restrictions on smoking, alcohol consumption and concomitant medications for this study during the study;
  21. Subjects who cannot stop high-intensity physical activities from the dosing day of the study drug until 30 days post-dose.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:基础科学
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
实验性的:BAT1706(New Process)

Drug: BAT1706

1 mg/kg, the corresponding volume of bulk solution should be drawn according to the actual body weight of the subject, diluted to 100 mL with 0.9% sodium chloride solution, and administered by intravenous drip

1 vial/carton, 400 mg/16 mL/vial

其他名称:
  • BAT1706
有源比较器:BAT1706(Old Process)

Drug: BAT1706

1 mg/kg, the corresponding volume of bulk solution should be drawn according to the actual body weight of the subject, diluted to 100 mL with 0.9% sodium chloride solution, and administered by intravenous drip

1 vial/carton, 400 mg/16 mL/vial

其他名称:
  • BAT1706

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
AUC0-inf
大体时间:Day1, 2, 3, 4, 5, 8,15, 22, 29, 36, 43, 57, 71

Area under the plasma concentration-time curve from zero to infinity, AUC0-∞ = AUC0-t + Ct/λz

Day1, 2, 3, 4, 5, 8,15, 22, 29, 36, 43, 57, 71
AUC0-t
大体时间:Day1, 2, 3, 4, 5, 8,15, 22, 29, 36, 43, 57, 71

Area under the blood concentration-time curve from time 0 to the last time point at which the concentration can be measured

Day1, 2, 3, 4, 5, 8,15, 22, 29, 36, 43, 57, 71
Cmax
大体时间:Day1, 2, 3, 4, 5, 8,15, 22, 29, 36, 43, 57, 71

Maximum blood concentration

Day1, 2, 3, 4, 5, 8,15, 22, 29, 36, 43, 57, 71
Tmax
大体时间:Day1, 2, 3, 4, 5, 8,15, 22, 29, 36, 43, 57, 71

Observed time to peak concentration

Day1, 2, 3, 4, 5, 8,15, 22, 29, 36, 43, 57, 71
t1/2
大体时间:Day1, 2, 3, 4, 5, 8,15, 22, 29, 36, 43, 57, 71

Elimination half-life t1/2 = 0.693/λz

Day1, 2, 3, 4, 5, 8,15, 22, 29, 36, 43, 57, 71

次要结果测量

结果测量
措施说明
大体时间
Adverse events
大体时间:Day1, 2, 3, 4, 5, 8,15, 22, 29, 36, 43, 57, 71

AE and SAE

Day1, 2, 3, 4, 5, 8,15, 22, 29, 36, 43, 57, 71
Immunogenicity
大体时间:Day1, 2, 3, 4, 5, 8,15, 22, 29, 36, 43, 57, 71

Anti-drug antibody (ADA) positivity, ADA titer and neutralizing antibody (NAb) positivity for ADA.

Day1, 2, 3, 4, 5, 8,15, 22, 29, 36, 43, 57, 71

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Wei Hu, Ph.D、The Second Hospital of Anhui Medical University

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2023年6月15日

初级完成 (实际的)

2023年9月21日

研究完成 (实际的)

2024年1月3日

研究注册日期

首次提交

2023年4月28日

首先提交符合 QC 标准的

2023年5月9日

首次发布 (实际的)

2023年5月19日

研究记录更新

最后更新发布 (实际的)

2026年10月1日

上次提交的符合 QC 标准的更新

2026年9月28日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

其他研究编号

  • BAT-1706-004-CR

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅